Humanized antibodies that recognize beta amyloid peptide
AssigneeElan Pharmaceuticals, Inc.
InventorsGuriq Basi, Jose Saldanha
Life of this patent
Estimating the term…
Abstract
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
Claims115
A humanized immunoglobulin light chain comprising variable region complementary determining regions (CDRS) from the 12B4 immunoglobulin light chain variable region sequence set forth as SEQ ID NO:2, and comprising variable framework regions from a human acceptor immunoglobulin light chain sequence, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 12B4 light chain variable region sequence, wherein the framework residue is selected from the group consisting of:
- (a) a residue that non-covalently binds antigen directly;
- (b) a residue adjacent to a CDR;
- (c) a CDR-interacting residue;
- and
- (d) a residue participating in the VL-VH interface.
A humanized immunoglobulin heavy chain comprising variable region complementary determining regions (CDRs) from the 12B4 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:4 and comprising variable framework regions from a human acceptor immunoglobulin heavy chain, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 12B4 heavy chain variable region sequence, wherein the framework residue is selected from the group consisting of:
- (a) a residue that non-covalently binds antigen directly;
- (b) a residue adjacent to a CDR;
- (c) a CDR-interacting residue;
- and
- (d) a residue participating in the VL-VH interface.
A humanized immunoglobulin light chain comprising variable region complementary determining regions (CDRs) from the 12B4 immunoglobulin light chain variable region sequence set forth as SEQ ID NO:2, and comprising variable framework regions from a human acceptor immunoglobulin light chain sequence, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 12B4 light chain variable region sequence, wherein the framework residue is a residue capable of affecting light chain variable region conformation or function as identified by analysis of a three-dimensional model of the variable region.
A humanized immunoglobulin heavy chain comprising variable region complementary determining regions (CDRs) from the 12B4 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:4, and comprising variable framework regions from a human acceptor immunoglobulin heavy chain, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 12B4 heavy chain variable region sequence, wherein the framework residue is a residue capable of affecting heavy chain variable region conformation or function as identified by analysis of a three-dimensional model of the variable region.
A light chain comprising the complementarity determining regions (CDRs) and variable region framework residue L2 (Kabat numbering convention) from the monoclonal antibody 12B4 light chain, wherein the remainder of the light chain is from a human immunoglobulin.
A heavy chain comprising the complementarity determining regions (CDRs) and variable framework residues H2, H24, H27, H29, H48, H49, H67, H71, and H78 (Kabat numbering convention) from the monoclonal antibody 12B4 heavy chain, wherein the remainder of the heavy chain is from a human immunoglobulin.
A heavy chain comprising the complementarity determining regions (CDRs) and variable framework residues H24, H27, H29 and H71 (Kabat numbering convention) from the monoclonal antibody 12B4 heavy chain, wherein the remainder of the heavy chain is from a human immunoglobulin.
A heavy chain comprising the complementarity determining regions (CDRs) and variable framework residues H24, H27, H29, H48, H71 and H78 (Kabat numbering convention) from the monoclonal antibody 12B4 heavy chain, wherein the remainder of the heavy chain is from a human immunoglobulin.
A humanized immunoglobulin comprising the light chain of any one of the preceding claims, and the heavy chain of any one of the preceding claims, or antigen-binding fragment of said immunoglobulin.
A humanized antibody comprising the complementary determining regions (CDR1, CDR2 and CDR3) of the 12B4 variable light chain sequence set forth as SEQ ID NO:2.
A humanized antibody comprising the complementary determining regions (CDR1, CDR2 and CDR3) of the 12B4 variable heavy chain sequence set forth as SEQ ID NO:4.
A humanized antibody, or antigen-binding fragment thereof, which specifically binds to beta amyloid peptide (Aβ), comprising a variable region comprising complementary determining regions (CDRs) corresponding to CDRs from the mouse 12B4 antibody.
A chimeric immunoglobulin comprising variable region sequence substantially as set forth in SEQ ID NO:2 or SEQ ID NO:4, and comprising constant region sequences from a human immunoglobulin.
A method of preventing or treating an amyloidogenic disease in a patient, comprising administering to the patient an effective dosage of the humanized immunoglobulin of any one of the preceding claims.
A method of preventing or treating Alzheimer's disease in a patient, comprising administering to the patient an effective dosage of the humanized immunoglobulin of any one of the preceding claims.
A pharmaceutical composition comprising the immunoglobulin of any one of claims the preceding claims and a pharmaceutical carrier.
An isolated polypeptide comprising a fragment of SEQ ID NO:2 selected from the group consisting of amino acids 43-58 of SEQ ID NO:2, amino acids 74-80 of SEQ ID NO:2 and amino acids 113-121 of SEQ ID NO:2.
An isolated polypeptide comprising amino acids 43-48 of SEQ ID NO:2, amino acids 74-80 of SEQ ID NO:2 and amino acids 113-121 of SEQ ID NO:2.
An isolated polypeptide comprising a fragment of SEQ ID NO:4 selected from the group consisting of amino acids 50-56 of SEQ ID NO:4, amino acids 71-86 of SEQ ID NO:4 and amino acids 118-131 of SEQ ID NO:4.
An isolated polypeptide comprising amino acids 50-56 of SEQ ID NO:4, amino acids 71-86 of SEQ ID NO:4 and amino acids 118-131 of SEQ ID NO:4.
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:6.
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:
- 10 and SEQ ID NO:12.
An isolated polypeptide comprising amino acid residues 20-131 of SEQ ID NO:2.
An isolated polypeptide comprising amino acid residues 20-142 of SEQ ID NO:4.
An isolated polypeptide comprising amino acid residues 21-132 of SEQ ID NO:6.
An isolated polypeptide comprising amino acid residues 20-142 of SEQ ID NO:8.
An isolated polypeptide comprising amino acid residues 20-142 of SEQ ID NO:10.
An isolated polypeptide comprising amino acid residues 20-142 of SEQ ID NO:
- 12.
An isolated nucleic acid molecule encoding the light chain of any one of the preceding claims.
An isolated nucleic acid molecule encoding the heavy chain of any one of the preceding claims.
An isolated nucleic acid molecule encoding the immunoglobulin of any one of the preceding claims.
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1 and SEQ ID NO:5.
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:
- 11.
A vector comprising the nucleic acid molecule of any of the preceding claims.
A host cell comprising the nucleic acid molecule of any of the preceding claims.
A transgenic animal expressing a polypeptide encoded by the nucleic acid molecule of any of the preceding claims.
A method of producing an antibody, or fragment thereof, comprising a fragment of SEQ ID NO:2 selected from the group consisting of amino acids 43-58 of SEQ ID NO:2, amino acids 74-80 of SEQ ID NO:2 and amino acids 113-121 of SEQ ID NO:2, said method comprising culturing a host cell comprising a nucleic acid molecule that encodes said antibody, or fragment thereof, under conditions such that the antibody or fragment is produced, and isolating said antibody from the host cell or culture.
A method of producing an antibody, or fragment thereof, comprising a fragment of SEQ ID NO:4 selected from the group consisting of amino acids 50-56 of SEQ ID NO:4, amino acids 71-86 of SEQ ID NO:4 and amino acids 118-131 of SEQ ID NO:4, said method comprising culturing a host cell comprising a nucleic acid molecule that encodes said antibody, or fragment thereof, under conditions such that the antibody or fragment is produced, and isolating said antibody from the host cell or culture.
A method for identifying residues amenable to substitution in a humanized 12B4 immunoglobulin variable framework region, comprising modeling the three-dimensional structure of the murine 12B4 variable regions based on a solved immunoglobulin structure and analyzing said model for residues capable of affecting 12B4 immunoglobulin variable region conformation or function, such that residues amenable to substitution are identified.
Use of the variable region sequence set forth as SEQ ID NO:2 or SEQ ID NO:4, or any portion thereof, in producing a three-dimensional image of a 12B4 immunoglobulin, 12B4 immunoglobulin chain, or domain thereof.
A methods of imaging amyloid deposits in the brain of a patient comprising administering to the patient an agent that specifically binds to Aβ, and detecting the antibody bound to Aβ.
A method of treating an amyloidogenic disease comprising administering to a patient having said amyloidogenic disease, a nucleic acid molecule that encodes an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:6 and a nucleic acid molecule that encodes an immunoglobulin heavy chain that comprises the amino acid sequence of SEQ ID NO:8, the amino acid sequence of SEQ ID NO:
- 10, or the amino acid sequence of SEQ ID NO:
- 12, under conditions such that said immunoglobulin chains are expressed, such that a beneficial therapeutic response in said patient is generated.
A method of preventing or treating a disease associated with amyloid deposits of Aβ in the brain of a patient, comprising administering to the patient an effective dosage of the humanized immunoglobulin of any one of the preceding claims.
The method of any of the preceding claims, wherein the patient is human.
A method for reducing plaque burden in a subject in need thereof comprising administering to the patient an effective dosage of the humanized immunoglobulin of any one of the preceding claims.
A humanized immunoglobulin of any one of the preceding claims, which comprises a Fc region having an altered effector function.
A method for reducing neuritic burden in a subject in need thereof comprising administering to the subject an effective dose of a humanized antibody which binds to an epitope within amino acids 3-7 of beta amyloid peptide (Aβ), wherein the antibody is of the IgG1 isotype.
A method for treating an amyloidogenic disease in a patient comprising administering to the patient an effective dose of a humanized antibody capable of reducing beta amyloid peptide (Aβ) burden and neuritic dystrophy in the patient, wherein the antibody binds to an epitope within amino acids 3-7 of Aβ and is of the IgG1 isotype.
A method for reducing beta amyloid peptide (Aβ) burden and neuritic dystrophy in a mammal comprising administering to the mammal an effective dose of a humanized antibody capable of reducing beta amyloid peptide (Aβ) burden and neuritic dystrophy, wherein the antibody binds to an epitope within amino acids 3-7 of Aβ and is of the IgG1 isotype.
A therapeutic composition comprising a humanized antibody of the IgG1 isotype which binds to an epitope within amino acids 3-7 of beta amyloid peptide (Aβ), wherein the antibody is capable of reducing neuritic burden in a subject.
A method for treating an amyloidogenic disease in a patient comprising administering to the patient an effective dose of a humanized antibody which binds to soluble beta amyloid peptide (Aβ) and reduces neuritic dystrophy in the patient, wherein the antibody binds to an epitope within amino acids 3-7 of Aβ and is of the IgG1 isotype.
A therapeutic composition comprising a humanized antibody of the IgG1 isotype which binds to soluble beta amyloid peptide (Aβ), wherein the antibody binds to an epitope within amino acids 3-7 of Aβ and is capable of reducing neuritic burden in a subject.
Dependencies are inferred from the claim text.